Vital Signs - Ocular Drug Delivery: Expanding the Field of Vision

Vital Signs - Ocular Drug Delivery: Expanding the Field of Vision

 

RELEASE DATE
30-Mar-2009
REGION
North America
Research Code: 9561-00-87-00-00
SKU: HC00565-NA-MR_04037
AvailableYesPDF Download

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
HC00565-NA-MR_04037

$1,500.00

$1,125.00save 25 %

DownloadLink
ENQUIRE NOW

Description

This issue of Vital Signs, released on March 30, 2009, provides a strategic overview of selected new technology approaches and opportunities in ocular drug delivery and ophthalmic pharmaceuticals. Additionally, a company spotlight is provided for Inotek Pharmaceuticals, a company developing focused on developing products from its research into the regulation of cellular responses to tissue damaging conditions such as hypoxia, ischemia-reperfusion, diabetes, glaucoma, and angiogenic dysregulation. Reimbursement and regulatory news from the FDA is also provided for the week of March 16, 2009.

Table of Contents

This week's issue:

Related Research
This issue of Vital Signs, released on March 30, 2009, provides a strategic overview of selected new technology approaches and opportunities in ocular drug delivery and ophthalmic pharmaceuticals. Additionally, a company spotlight is provided for Inotek Pharmaceuticals, a company developing focused on developing products from its research into the regulation of cellular responses to tissue damaging conditions such as hypoxia, ischemia-reperfusion, diabetes, glaucoma, and angiogenic dysregulation. Reimbursement and regulatory news from the FDA is also provided for the week of March 16, 2009.
More Information
No Index Yes
Podcast No
Industries Healthcare
WIP Number 9561-00-87-00-00
Is Prebook No